Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 9/20 | 0.83 |
| ▸ | MEN1 | O00255 | 8/20 | 0.83 |
| ▸ | MAPT | P10636 | 2/20 | 0.75 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.75 |
| ▸ | RAB9A | P51151 | 1/20 | 0.75 |
| ▸ | HPGD | P15428 | 3/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.73 |
| ▸ | POLB | P06746 | 2/20 | 0.73 |
| ▸ | THRB | P10828 | 1/20 | 0.73 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.73 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.73 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.71 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11080652 | 0.93 | KMT2A (0.71) | KMT2AMEN1MAPTKDM4ERAB9A | |
| SCHEMBL11080648 | 0.93 | KMT2A (0.71) | KMT2AMEN1MAPTKDM4ERAB9A | |
| SCHEMBL11083582 | 0.91 | KMT2A (0.82) | KMT2AMEN1MAPTKDM4ERAB9A | |
| SCHEMBL11083586 | 0.91 | KMT2A (0.82) | KMT2AMEN1MAPTKDM4ERAB9A | |
| SCHEMBL11083512 | 0.89 | KMT2A (0.72) | KMT2AMEN1MAPTKDM4ERAB9A | |
| SCHEMBL11083516 | 0.89 | KMT2A (0.72) | KMT2AMEN1MAPTKDM4ERAB9A | |
| SCHEMBL23760329 | 0.88 | POLB (0.88) | KMT2AMEN1MAPTKDM4ERAB9A | |
| SCHEMBL11088366 | 0.87 | POLB (0.66) | KMT2AMEN1MAPTKDM4ERAB9A | |
| SCHEMBL11088364 | 0.87 | POLB (0.66) | KMT2AMEN1MAPTKDM4ERAB9A | |
| SCHEMBL10851779 | 0.86 | KMT2A (0.74) | KMT2AMEN1MAPTKDM4ERAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11701406-B2 | Combination of low dose IL-2 and an inhibitor of Treg IL-2R desensitization to treat autoimmune and allergic inflammatory diseases | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2023-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11701406-B2 | Combination of low dose IL-2 and an inhibitor of Treg IL-2R desensitization to treat autoimmune and allergic inflammatory diseases | NEDD8, NAE1, UBE2T | KMT2A 244/4885MEN1 3271/4885MAPT 2314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.